endTB in Kazakhstan

Implementer: Partners In Health

Site: National Center for TB Problems of the MOHSD of Kazakhstan, Almaty City, Astana City, Almaty Oblast, Zhambyl Oblast and Akmolinskaya Oblast  

Lilia (left) is the first patient to receive Bedaquiline in Almaty, Kazakhstan. (Photo by Yekaterina Sahabutdinova / Partners In Health)
Lilia (left) is the first patient to receive Bedaquiline in Almaty, Kazakhstan. (Photo by Yekaterina Sahabutdinova / Partners In Health)

 

Kazakhstan, a Central Asian country, has one of the highest numbers of MDR-TB patients in the world. 25% of newly diagnosed TB patients and 43% of retreatment cases have MDR-TB. PIH supported the National Tuberculosis Program (NTP) in scaling up MDR-TB treatment, especially in the prison sector, leading to enrolment of more than 900 patients across the country. 

PIH maintains a close relationship with the NTP and has contributed to the development of national decree and guidelines on MDR-TB that have been approved by the Ministry of Health for scale-up. 

PIH MSF MSF UNITAID